Mindset Health · AI therapeutics

Mindovermatter.

What the brain does, the body feels. Clinically validated programs for the chronic conditions drugs weren’t built for.

  • 350,000+ patients
  • 10+ published studies
  • 20,000+ referring providers
  • 30M+ covered lives
Scroll to explore
Problem

Where current care runs out.

Chronic pain, IBS, menopause, and anxiety affect about one in four adults. Most are already in care. Most still have symptoms. Years of medications, specialists, and elimination diets move the needle a little, and leave most of the burden on patients, the clinicians who treat them, and the systems that pay for the cycle. For these conditions, the body follows the brain. Drugs don’t reach the wiring.

1 in 4 adults
live with chronic pain (CDC, 2024). 1 in 5 with anxiety or depression (NIMH).
Treated, but not resolved.
On first-line drugs, two-thirds of IBS patients miss the responder threshold (Chey, AJG 2012).
The mechanism is neural, not chemical.
Drug discovery was built for molecular targets.
A different therapeutic substrate.
Software that trains the brain–body axis, validated in randomised trials.
What we do

Programs built on techniques that address the nervous system, not just the symptom.

How we think and feel changes how the body functions. Gut motility. Pain perception. Autonomic regulation. For the chronic conditions where pharmacology under-performs, this brain–body axis is the dominant pathology. Behavioral techniques can engage it. We turn them into software. Adapted to each user. Run from a phone. Measured against the same endpoints as a drug trial.

350k+
People helped
30M+
Covered lives
10+
Published studies
See how the model works
How it works

Brain–body techniques at the speed of software.

01 · Assess

Validated symptom tracking

The model meets each person where they are. Symptoms, history, goals, signals.

02 · Adapt

A program shaped to you

Every audio session, lesson and exercise adapts to your progress. No two programs run the same.

03 · Improve

Outcomes you can measure

Continuous feedback drives the model, and clinically meaningful improvement, week over week.

RESEARCH

Clinically studied outcomes measured against active controls.

Abdominal pain score over 42 sessions · Anderson, AJG 2025 · n=244
3040506070Abdominal painBaseline71421283542Sessions
Nerva (n=122) Active control (n=122)
71%

of participants experienced clinically significant abdominal pain reduction at 6 weeks, vs. 35% on active control, in a peer-reviewed gut-directed hypnotherapy trial.1

  • Published studies10+
  • Patients helped350,000+
  • Randomised trialsIncluding AJG 2025 flagship
Source: Anderson, Peters, Gibson, Halmos · AJG 2025. Results from a peer-reviewed study; individual outcomes vary.
See all research
Working with researchers from:
Monash UniversityMassachusetts General HospitalMayo ClinicMount SinaiNeuRA
Voices

Stories of change

I can eat normally again
Nerva helped me rewire my vagus nerve communication. Now my gut talks to my brain in a way that doesn't signal panic. I can cook and eat normally again. I can go to restaurants.
PatientSkateymac, App Store
No more panic
Get in touch

Partner with us to expand access to care.